Randox: Improving chest pain diagnosis
New medical research is promoting the early and more accurate diagnoses of disease states by identifying new ‘biomarkers', released into the blood or other body fluids as a result of disease
New medical research is promoting the early and more accurate diagnoses of disease states by identifying new 'biomarkers', released into the blood or other body fluids as a result of disease.
Because the human response to disease is complex, the simultaneous assessment of multiple biomarkers makes it possible for clinicians to accurately identify a disease - and decide on the most appropriate treatments - much earlier than before. In the vast majority of cases, early diagnosis leads to improved patient outcomes and considerable savings for healthcare budgets.
Randox Laboratories leads the way in the simultaneous testing of biomarkers for clinical use. Based on the revolutionary Randox 'Biochip', currently up to 50 tests can be conducted at the same time, with comprehensive data provided quickly to the clinician.
The company has also developed a range of diagnostic applications, covering cardiovascular diseases, stroke, a range of cancers, metabolic syndrome, respiratory diseases and sexually transmitted diseases - with many more under development.
The cardiac biochip, for example, enables the early identification of a heart attack. By combining biomarkers, Randox's solution achieves 20% greater sensitivity than the current 'gold-standard' test, and enables A&E clinicians to rule out non-heart attack victims much earlier than before. This allows patients to be stratified according to risk, with those at higher risk given priority treatment.
This approach will not only save lives but will reduce unnecessary hospital admissions, easing the pressure on bed spaces. In England alone, it has the potential to save the NHS £830m over five years.
What do you think about this case study?
Be in touch and let us know
